1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kexing Biopharm Co., Ltd. Class A

Kexing Biopharm Co., Ltd. Class A

SSSE:688136
20.30
CNY
+0.75
(+3.84%)
1.15EPS
17.64P/E
4.17BMarket Cap
Oct 30Next Earn
Kexing Biopharm Co., Ltd. Class A
SSE:688136
(Shanghai Stock Exchange)

Recent

price

20.30

P/E

ratio

17.64

div

yld

2.67%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
10.06
14.57
7.97
8.16
6.53
6.56
6.35
7.15
7.79
6.75
Revenue per Share
0.97
1.54
1.07
0.93
0.49
-0.45
-0.96
0.16
0.79
1.17
Basic EPS, GAAP
0.15
0.38
-0.32
-0.56
-1.41
-2.42
-1.4
0.06
0.01
- -
Free Cash Flow per Basic Share
0.79
0.16
0.05
0.07
0.14
0.27
0.23
0.22
0.29
0.54
Dividend per Share
1.42
3.32
4.67
9.21
9.62
9.1
8.16
8.19
8.7
9.13
Book Value per Share
1.24
3.08
4.44
9.03
9.48
8.27
7.37
6.91
7.15
7.52
Tangible Book Value per Share
61
61
149
150
197
201
198
197
197
198
Basic Weighted Avg Shares
616
891
1,191
1,220
1,285
1,316
1,259
1,407
1,534
1,340
Sales/Revenue/Turnover
16.33
15.95
17.63
15.06
3.56
-9.1
-18.46
9.18
6.36
-3.9
Operating Margin (%)
19
21
24
29
50
71
88
101
109
- -
Depreciation Expense
59
94
160
139
96
-90
-190
31
156
233
Net Income, GAAP
20.41
22.35
14.9
12.58
- -
- -
- -
52.47
7.82
7.82
Effective Tax Rate (%)
9.64
10.57
13.42
11.4
7.51
-6.86
-15.11
2.24
10.14
17.38
Profit Margin (%)
-145
169
208
1,200
857
872
464
401
586
386
Working Capital
11
10
9
123
307
804
714
626
730
681
LT Debt
212
494
696
1,830
1,911
1,806
1,631
1,639
1,753
1,838
Total Equity
- -
20.36
21.06
9.09
- -
- -
- -
1.08
5.19
7.39
Return on Invested Capital (%)
- -
22.42
21.59
9.53
- -
- -
- -
2.02
6.56
8.83
Return on Capital (%)
- -
26.65
26.84
11.01
5.16
-4.86
-11.08
1.93
9.19
13.31
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
667
717
778
LT Borrowings
728
685
675
LT Finance Leases
2
8
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
201
201
201
Market Capitalization
6,374
5,957
4,168

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,607
1,553
1,507
Cash, Cash Equivalents & STI
650
628
610
Accounts Receivable, Net
580
588
558
Inventories
139
155
136
Total Current Liabilities
1,021
1,037
1,121
Payables & Accruals
- -
- -
- -
ST Debt
667
717
778
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-0.67%
6.91%
Free Cash Flow
- -
16.21%
-81.05%
Net Income, GAAP
- -
32.82%
394.17%
Sales/Revenue/Turnover
- -
4.83%
9.03%
Total Cash Common Dividend
- -
52.48%
31.51%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
361
399
278
369
1,407
2025
354
347
- -
386
1,534
2026
281
327
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
0.03
0.07
0.16
2025
0.13
0.28
- -
0.22
0.79
2026
-0.09
0.77
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.06
0.06
0.05
0.22
2025
0.05
0.13
- -
0.05
0.29
2026
0.05
0.3
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kexing Biopharm Co., Ltd. (688136.SS) is a China-based innovative biopharmaceutical company engaged in the research, development, production and commercialization of recombinant protein drugs and microecological preparations; it focuses on therapeutic areas including antiviral treatments, oncology, immunology, hematology, digestive diseases and degenerative conditions, with core products encompassing Recombinant Human Erythropoietin Injection (EPOSINO), Recombinant Human Interferon α1b for Injection (SINOGEN), Recombinant Human Granulocyte Colony-Stimulating Factor Injection (WHITE-C), Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule (CLOBICO), Albumin-bound Paclitaxel (Apexelsin) and Infliximab for Injection (Reminton), alongside a pipeline of over a dozen projects such as GB05 Human Interferon α1b Inhalation Solution in Phase III trials, GB-K02 Long-acting G-CSF in Phase III and novel bispecific/trispecific antibodies targeting solid tumors, inflammatory bowel disease and atopic dermatitis. Founded in 1997 and headquartered in Jinan, Shandong province, the company operates R&D centers in Shenzhen, Shandong and Guangzhou, leveraging advanced platforms including prokaryotic/eukaryotic cell technologies, KX-FUSION fusion protein, KX-BODY antibody, exosome delivery and microecological agent systems; its products reach over 20,000 domestic terminals including 8,000 hospitals and 3,000 pharmacies in China, with exports to more than 70 countries and regions across Europe, Brazil, the Philippines, Indonesia and Peru through six overseas subsidiaries and a "Global Product Selection + Global Product Coverage" strategy. Recent developments include a strategic partnership with IQVIA announced in August 2025 to accelerate global clinical development, regulatory approvals and market access for its innovative drugs and biosimilars in Europe and other markets; approval of sorafenib in Peru in September 2025; inclusion of α1b inhalation solution for pediatric respiratory conditions in China's breakthrough therapy designation in September 2025; and US FDA DMF filing acceptance for exosome raw materials in September 2025, alongside recognition in China's top 20 biopharmaceutical enterprises for blood products, vaccines and insulin in 2024.